We hypothesized that in vivo delivery of the mutant p53 small-molecule reactivator, PRIMA-1Met would restore wild-type p53 in mutant p53 (R273C) tumor cells (GBM22) by affecting p53′s canonical role in tumor growth, as well as the non-canonical role regarding xCT expression and function. This evidence concerns the gene SLC7A11 and neoplasm.